摘要
目的观察吉西他滨单药周剂量治疗老年晚期非小细胞肺癌的疗效和不良反应。方法对45例老年晚期非小细胞肺癌患者（年龄≥65岁）应用吉西他滨800~1000 mg/m2,第1、8天,3~4周为1个周期,至少治疗2个周期评价疗效和不良反应。结果全组总有效率为26.7%（12/45）,临床受益率为71.1%（32/45）,无疾病进展生存时间为4.2个月,中位生存时间为8.3个月,1年生存率为31.1%（14/45）,主要不良反应为骨髓抑制、胃肠道反应、皮疹和肝肾功能受损。结论吉西他滨单药周剂量治疗老年晚期非小细胞肺癌耐受性较好,生活质量较高。
Objective To observe the clinical efficacy and toxicity of gemcitabine monotherapy in treatment of eldly patients with advanced non-small cell lung cancer（NSCLC）.Methods 45 elderly patients（age≥65 years） with advanced NSCLC diagnosed pathologically were treated with gemcitabine 8001000mg / m2on d1、8,every 3 ~ 4 weeks,Each patient was given at least 2 cycles.And the efficacy and toxicity were then evaluated.Results In the 45 cases evaluable,The objective response rate was 26.7%,and MST was 8.3 months,and one-year survival rates was 31.1%.Main side effects was decrease of leukopenia and platelet,gastroenteric reaction,efflorescence,and impaired renal and liver function.Conclusions Gemcitabine monotherapy is effective and safe in treatment of eldly patients with advanced NSCLC.
出处
《中国肿瘤临床与康复》
2013年第8期852-854,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
吉西他滨
非小细胞肺癌
药物疗法
老年
Gemcitabine
Non-small cell lung cancer
Drug therapy
Aged
